Top 8 Highlights From the ESMO 2014 Congress
This slide show features some of the top highlights on breast, prostate, and lung cancers to come out of the European Society for Medical Oncology 2014 Congress.
References:
1. Swain S, Kim S, Cortes J, et al. Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). European Society for Medical Oncology (ESMO) 2014 Congress. Abstract 350O.
2. Yao JC, Pavel M, Lombard-Bohas C, et al. (EVE) for the treatment of advanced pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results of a randomized, double-blind, placebo (PBO)-controlled, multicenter Phase III trial (RADIANT-3). European Society for Medical Oncology (ESMO) 2014 Congress. Abstract 1132O.
3. Weber JS, Minor D, D'Angelo S, et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. European Society for Medical Oncology (ESMO) 2014 Congress. Abstract LBA3.
4. Samuel N, Verma S. Cross-comparison of cancer drug approvals among international regulatory bodies. European Society for Medical Oncology (ESMO) 2014 Congress. Abstract 1036O.
5. Antonia S, Goldberg S, Balmanoukian A, et al. A Phase I open-label study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death-ligand 1(PD-L1) antibody, in combination with tremelimumab in patients with advanced non-small cell lung cancer (NSCLC). European Society for Medical Oncology (ESMO) 2014 Congress. Abstract 1327P.
6. McArthur G, Ascierto P, Larkin J, et al. Phase 3, double-Blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation-positive patients with unresectable locally advanced or metastatic melanoma. European Society for Medical Oncology (ESMO) 2014 Congress. Abstract LBA5.
7. Shaw AT, Ou S, Bang Y, et al. Clinical activity of crizotinib in ROS1-rearranged non-small cell lung cancer. European Society for Medical Oncology (ESMO) 2014 Congress. Abstract 1299P.
8. Ryan C, Smith M, Fizazi K, et al. Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy. European Society for Medical Oncology (ESMO) 2014 Congress. Abstract 753O.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
